Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Pharmacogenetic association of the galanin receptor (GALR1) SNP rs2717162 with smoking cessation.

Gold AB, Wileyto EP, Lori A, Conti D, Cubells JF, Lerman C.

Neuropsychopharmacology. 2012 Jun;37(7):1683-8. doi: 10.1038/npp.2012.13.

2.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
3.

Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials.

Lerman C, Jepson C, Wileyto EP, Epstein LH, Rukstalis M, Patterson F, Kaufmann V, Restine S, Hawk L, Niaura R, Berrettini W.

Neuropsychopharmacology. 2006 Jan;31(1):231-42.

4.

Pharmacological interventions for smoking cessation: an overview and network meta-analysis.

Cahill K, Stevens S, Perera R, Lancaster T.

Cochrane Database Syst Rev. 2013 May 31;(5):CD009329. doi: 10.1002/14651858.CD009329.pub2. Review.

PMID:
23728690
5.

Nicotine replacement therapy for smoking cessation.

Silagy C, Mant D, Fowler G, Lancaster T.

Cochrane Database Syst Rev. 2000;(3):CD000146. Review. Update in: Cochrane Database Syst Rev. 2001;(3):CD000146.

PMID:
10908462
6.

Nicotine replacement therapy for smoking cessation.

Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T.

Cochrane Database Syst Rev. 2012 Nov 14;11:CD000146. doi: 10.1002/14651858.CD000146.pub4. Review.

PMID:
23152200
7.

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation.

David SP, Brown RA, Papandonatos GD, Kahler CW, Lloyd-Richardson EE, Munafò MR, Shields PG, Lerman C, Strong D, McCaffery J, Niaura R.

Nicotine Tob Res. 2007 Aug;9(8):821-33. Erratum in: Nicotine Tob Res. 2007 Nov;9(11):1243.

8.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD006103. doi: 10.1002/14651858.CD006103.pub5. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD006103.

PMID:
21328282
9.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2010 Dec 8;(12):CD006103. doi: 10.1002/14651858.CD006103.pub4. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD006103.

PMID:
21154363
10.

Interventions for smoking cessation and reduction in individuals with schizophrenia.

Tsoi DT, Porwal M, Webster AC.

Cochrane Database Syst Rev. 2013 Feb 28;(2):CD007253. doi: 10.1002/14651858.CD007253.pub3. Review.

PMID:
23450574
11.

Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking.

Tyndale RF, Zhu AZ, George TP, Cinciripini P, Hawk LW Jr, Schnoll RA, Swan GE, Benowitz NL, Heitjan DF, Lerman C; PGRN-PNAT Research Group..

PLoS One. 2015 May 26;10(5):e0128109. doi: 10.1371/journal.pone.0128109.

12.

Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6).

Chen LS, Bloom AJ, Baker TB, Smith SS, Piper ME, Martinez M, Saccone N, Hatsukami D, Goate A, Bierut L.

Addiction. 2014 Jan;109(1):128-37. doi: 10.1111/add.12353.

13.

Efficacy and tolerability of pharmacotherapies to aid smoking cessation in adolescents.

Bailey SR, Crew EE, Riske EC, Ammerman S, Robinson TN, Killen JD.

Paediatr Drugs. 2012 Apr 1;14(2):91-108. doi: 10.2165/11594370-000000000-00000. Review.

14.

Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.

Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, Ascher J, Russ C, Krishen A, Evins AE.

Lancet. 2016 Jun 18;387(10037):2507-20. doi: 10.1016/S0140-6736(16)30272-0.

PMID:
27116918
15.

Nicotinic acetylcholine receptor beta2 subunit (CHRNB2) gene and short-term ability to quit smoking in response to nicotine patch.

Perkins KA, Lerman C, Mercincavage M, Fonte CA, Briski JL.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2608-12. doi: 10.1158/1055-9965.EPI-09-0166.

16.

Outcomes from an outpatient smoking-cessation clinic.

Roth MT, Andrus MR, Westman EC.

Pharmacotherapy. 2005 Feb;25(2):279-88.

PMID:
15767242
17.

Pharmacogenetic investigation of smoking cessation treatment.

Lerman C, Shields PG, Wileyto EP, Audrain J, Pinto A, Hawk L, Krishnan S, Niaura R, Epstein L.

Pharmacogenetics. 2002 Nov;12(8):627-34.

PMID:
12439223
18.

Nicotine receptor partial agonists for smoking cessation.

Cahill K, Stead LF, Lancaster T.

Cochrane Database Syst Rev. 2008 Jul 16;(3):CD006103. doi: 10.1002/14651858.CD006103.pub3. Review. Update in: Cochrane Database Syst Rev. 2010;(12):CD006103.

PMID:
18646137
19.

Nicotinic acetylcholine receptor variation and response to smoking cessation therapies.

Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, Liu J, Lee W, Edlund CK, Hall S, Kwok PY, Benowitz NL, Baker TB, Tyndale RF, Lerman C, Swan GE.

Pharmacogenet Genomics. 2013 Feb;23(2):94-103. doi: 10.1097/FPC.0b013e32835cdabd.

20.

CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial.

Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, Tyndale RF.

Biol Psychiatry. 2007 Sep 15;62(6):635-41.

PMID:
17223085
Items per page

Supplemental Content

Support Center